Literature DB >> 26252118

New class PCSK9 blockers stride into cholesterol market.

Cormac Sheridan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26252118     DOI： 10.1038/nbt0815-785

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  Biologics inch toward cholesterol-lowering market.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2012-04-10       Impact factor: 54.908

2.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Authors:  Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Amy McCagg; Jennifer A White; Pierre Theroux; Harald Darius; Basil S Lewis; Ton Oude Ophuis; J Wouter Jukema; Gaetano M De Ferrari; Witold Ruzyllo; Paul De Lucca; KyungAh Im; Erin A Bohula; Craig Reist; Stephen D Wiviott; Andrew M Tershakovec; Thomas A Musliner; Eugene Braunwald; Robert M Califf
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

Review 3.  Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.

Authors:  Erik S Stroes; Paul D Thompson; Alberto Corsini; Georgirene D Vladutiu; Frederick J Raal; Kausik K Ray; Michael Roden; Evan Stein; Lale Tokgözoğlu; Børge G Nordestgaard; Eric Bruckert; Guy De Backer; Ronald M Krauss; Ulrich Laufs; Raul D Santos; Robert A Hegele; G Kees Hovingh; Lawrence A Leiter; Francois Mach; Winfried März; Connie B Newman; Olov Wiklund; Terry A Jacobson; Alberico L Catapano; M John Chapman; Henry N Ginsberg
Journal:  Eur Heart J       Date:  2015-02-18       Impact factor: 29.983

4.  Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.

Authors:  Peter H Jones; Radhika Nair; Kamlesh M Thakker
Journal:  J Am Heart Assoc       Date:  2012-12-19       Impact factor: 5.501
  4 in total
  6 in total

1.  AbbVie buys last available priority voucher for $350 million.

Authors:  Chris Morrison
Journal:  Nat Biotechnol       Date:  2015-11       Impact factor: 54.908

2.  Pfizer drops phase 3 lipid-lowering antibody.

Authors: 
Journal:  Nat Biotechnol       Date:  2016-12-07       Impact factor: 54.908

3.  Amgen cholesterol antibody feud could kill key IP rule.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2017-12-08       Impact factor: 54.908

4.  GENETICS. Strength in small numbers.

Authors:  Sarah Tishkoff
Journal:  Science       Date:  2015-09-18       Impact factor: 47.728

Review 5.  Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway.

Authors:  Green Ahn; Steven M Banik; Carolyn R Bertozzi
Journal:  Cell Chem Biol       Date:  2021-03-25       Impact factor: 9.039

6.  Heparan sulfate proteoglycans present PCSK9 to the LDL receptor.

Authors:  Camilla Gustafsen; Ditte Olsen; Joachim Vilstrup; Signe Lund; Anika Reinhardt; Niels Wellner; Torben Larsen; Christian B F Andersen; Kathrin Weyer; Jin-Ping Li; Peter H Seeberger; Søren Thirup; Peder Madsen; Simon Glerup
Journal:  Nat Commun       Date:  2017-09-11       Impact factor: 14.919
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.